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Monitoring of dynamic changes 
in Keyhole Limpet Hemocyanin 
(KLH)-specific B cells in KLH-
vaccinated cancer patients
Florian Wimmers1, Nienke de Haas1, Anja Scholzen2, Gerty Schreibelt1, Elles Simonetti3, 
Marc J. Eleveld3, Huberdina M. L. M. Brouwers4, Marjo Beldhuis-Valkis4, Irma Joosten4, 
Marien I. de Jonge3, Winald R. Gerritsen5, I. Jolanda M. de Vries1,5,*, Dimitri A. Diavatopoulos3,* 
& Joannes F. M. Jacobs4
Keyhole limpet hemocyanin (KLH) is used as an immunogenic neo-antigen for various clinical 
applications and during vaccine development. For advanced monitoring of KLH-based interventions, 
we developed a flow cytometry-based assay for the ex vivo detection, phenotyping and isolation of 
KLH-specific B cells. As proof-of-principle, we analyzed 10 melanoma patients exposed to KLH during 
anti-cancer dendritic cell vaccination. Our assay demonstrated sensitive and specific detection of KLH-
specific B cells in peripheral blood and KLH-specific B cell frequencies strongly correlated with anti-KLH 
serum antibody titers. Profiling of B cell subsets over the vaccination course revealed that KLH-specific 
B cells matured from naïve to class-switched memory B cells, confirming the prototypic B cell response 
to a neo-antigen. We conclude that flow-cytometric detection and in-depth phenotyping of KLH-
specific B cells is specific, sensitive, and scalable. Our findings provide novel opportunities to monitor 
KLH-specific immune responses and serve as a blueprint for the development of new flow-cytometric 
protocols.
Keyhole limpet hemocyanin (KLH) is a high-molecular-weight glycoprotein of marine origin that induces 
both cell-mediated and humoral responses in animals and humans. Because of its potent immunogenicity, its 
low-grade toxicity and its availability as a clinical grade product, KLH is used extensively as a natural immu-
nostimulant for basic research and clinical applications1–3. As a neo-antigen, KLH is ideally suited to study T 
cell-dependent primary and secondary immune responses and a recent study highlights its ability to stimulate 
the innate immune system. KLH was first introduced into the clinic in 1967 to assess immunocompetence of 
individuals4. KLH is currently mainly employed as standard carrier protein for the production of monoclonal 
antibodies to haptens such as peptides and oligosaccharides1. Besides this, KLH has been studied as a local treat-
ment for patients with bladder cancer, but proved to be inferior to mitomycin treatment5,6. Finally, KLH has 
progressed into clinical trials as either a carrier protein, an adjuvant- or immunomonitoring tool in a variety 
of cancer vaccines7,8 and immunotherapeutic strategies against chronic infections and autoimmune disease9,10. 
Strong inter-individual differences are typically observed in the immunological and clinical responses of individ-
uals exposed to KLH8. In-depth information about the dynamics and phenotype of the KLH-specific immune 
response may help to optimize its clinical use and provide biomarkers for selecting patients that will benefit most 
from KLH-based interventions.
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We currently lack appropriate monitoring tools that allow a detailed study of the KLH-specific B cell response. 
So far, B cell responses to KLH have mainly been evaluated by quantifying KLH-specific antibodies in serum11–16. 
Direct longitudinal analysis of KLH-specific B cells in peripheral blood could provide novel information 
on the magnitude and phenotype of the KLH-specific B cell response. A number of recent studies employed 
fluorescently-labeled antigens to directly monitor vaccine-, virus- or allergen-induced antigen-specific B cells17–20.
In this study, we established a novel flow-cytometric assay to detect, phenotype and isolate KLH-specific 
B cells in peripheral blood in a sensitive and specific manner. As proof of concept, we applied our novel assay 
to monitor KLH-specific B cell responses in a cohort of cancer patients that were vaccinated with autologous 
monocyte-derived matured dendritic cells (DC) loaded with KLH and tumor antigen. We found that the serum 
concentration of KLH-specific antibodies was highly correlated to the number and phenotype of KLH-specific 
B cells. Flow-cytometric isolation of the fluorescently labeled KLH-specific B cells allowed ex vivo production of 
KLH-specific antibodies and confirmed the high specificity of the assay. By analyzing B cell maturation, we were 
able to visualize the dynamics of KLH-specific B cells following primary as well as booster vaccination.
Our novel assay allows detailed cellular monitoring of the KLH-specific B cell response. Applying this tech-
nique to the field of KLH-based interventions could provide new insight into the origin, development and main-
tenance of the KLH-specific response and may facilitate the development of novel KLH-applications.
Results
To gain an understanding of the B cell response to KLH, we set out to examine the frequency and phenotype of 
KLH-specific B cells across the DC vaccination course of 10 stage III melanoma patients (Supplementary Table 1). 
To cover multiple stages of humoral immunity, we selected three time points during treatment to measure the 
primary response as well as the recall response within each patient. To examine the primary response, baseline 
frequencies were determined 7–22 days before vaccination and after injection number 2–4 of the 1st cycle (des-
ignated 1st cycle). Recall responses were determined after 3 injections of the 3rd vaccination cycle (designated 3rd 
cycle).
Detection of KLH-specific B cells via flow cytometry is specific and sensitive. First, we sought 
to verify the specificity and sensitivity of the flow cytometry-based detection assay here presented. For this 
purpose, PBMC samples were stained for common leukocyte markers, together with two preparations of 
fluorescently-labeled KLH using either FITC or ReadiLink 700/713. KLH-specific B cells were defined as dou-
ble positive cells (KLH++) within the CD19+ CD3−CD14−CD16−CD56− population (Fig. 1a). We employed 
fluorescence-activated cell sorting to isolate live CD19+ KLH++ and CD19+ KLH−− B cells from patients 5 and 9 
during their 3rd cycle of vaccination. Following sorting, cells were stimulated in vitro for six days to differentiate 
them into antibody secreting cells (ASCs). ELISPOT was then used to determine the total number of Ig-secreting 
ASCs as well as the number of KLH-specific B cells. Although both CD19+ KLH++ and CD19+ KLH−− B cells 
secreted detectable amounts of total IgG antibodies after in vitro differentiation (Fig. 1b), only the CD19+ KLH++ 
cells produced KLH-specific antibodies. Enumeration of duplicate wells of CD19+ KLH++ B cells in patient 9 
showed that nearly all IgG-secreting B cells were specific for KLH (Fig. 1c), suggesting a high specificity of the 
assay. Similar findings were observed for IgM and IgA (Fig. 1d–f).
To determine the frequency of circulating KLH-specific B cells via ELISPOT, total CD19+ B cells were sorted, 
differentiated into ASCs and seeded on ELISPOT plates either coated with KLH protein or anti-IgG antibodies 
(Fig. 2a). Although some variation was observed in the number of IgG-secreting cells per 1000 seeded cells (n = 5 
technical replicates, representative for 4 samples), the frequency of anti-KLH IgG antibody producing cells per 
1000 cells remained constant (Fig. 2b). To estimate the frequency of KLH-specific IgG+ B cells within the sorted B 
cell population, we determined the ratio of KLH IgG : total IgG ASCs (Fig. 2c). The corresponding ratio was lower 
yet similar to the frequency of KLH++ CD19+ IgG+ cells, as determined by flow cytometry, suggesting that flow 
cytometry has a similar sensitivity to ELISPOT.
Frequency of circulating KLH-specific B cells correlates with anti-KLH antibody serum titers. 
Next, we correlated the frequency of KLH++ cells as determined by flow cytometry with serum levels of anti-KLH 
antibody titers (Fig. 3). Spearman’s rank-order correlation analysis revealed a strong, positive correlation between 
the frequency of CD19+ KLH++ cells and anti-KLH IgG serum titers (rS = 0.91, p = 2·10−10, n = 26). This corre-
lation was further improved when comparing serum titers with the frequency of KLH++ cells within the CD19+ 
IgG+ subpopulation but not the CD19+ CD38+−IgG+ CD27+ subpopulation, which has previously been asso-
ciated with high levels of somatic hyper mutation and a high degree of proliferative potential21. Similar correla-
tions, though to a weaker extent, could be found for anti-KLH IgA serum titers and anti-KLH IgM serum titers 
(Supplementary Figure 1).
KLH-specific B cell dynamics and phenotype. Next, we assessed to what extent KLH exposure induced 
expansion of KLH-specific B cells in our patient cohort (Fig. 4). The baseline frequency of KLH++ CD19+ B cells 
was low and did not exceed 0.005% of CD19+ B cells. After the 1st cycle, we detected a moderate ~10-fold increase 
in KLH++ B cells in a subset of 3 patients (Fig. 4a,b). After the 3rd cycle, a massive > 100-fold expansion was 
observed in all patients analyzed, reaching frequencies of KLH-specific B cells as high as 1.3% of the total B cell 
pool (CD19+) and 8.9% of the class switched memory B cells (CD19+ IgG+).
To further investigate the phenotype of the KLH-specific B cells, we compared changes in expression of 
cell maturation markers after 1 and 3 cycles of vaccination (Fig. 5). B cell subsets were defined as described 
(Supplementary Figure 2, Supplementary M&M). After the 1st cycle, CD19+ KLH++ were predominantly 
unswitched IgM+ CD27+ cells. Conversely, after the 3rd cycle, the vast majority of CD19+ KLH++ cells were class 
www.nature.com/scientificreports/
3Scientific RepoRts | 7:43486 | DOI: 10.1038/srep43486
switched B cells and predominantly displayed a IgG+ CD27+ phenotype, indicative for repeated antigen expo-
sure and late memory differentiation. These maturation changes were specifically observed in the KLH-specific 
B cell fraction and not in the total CD19+ B cell population, which was dominated by IgM+ CD27− naïve B cells 
throughout the entire treatment period, suggesting that these changes specifically occur in KLH-specific B cells.
Finally, we analyzed the dynamics of KLH-specific B cell development during the complete course of DC 
vaccination in patient 5 (Fig. 6). Increased frequencies of KLH++ B cells could already be detected after three 
injections of DCs, in accordance with an increase in anti-KLH Ig titers in serum (Fig. 6a). However, the strongest 
increase in KLH++ B cells was observed after the first vaccination during the 2nd and 3rd cycle. This increase in 
KLH-specific B cells was accompanied by an increase in anti-KLH IgG antibody titers. Immunophenotyping of 
KLH-specific B cells confirmed the dynamic changes observed in the serum titers, demonstrating a classical pat-
tern of primary and secondary B cell response (Fig. 6b). Initially, the KLH-specific B cell response was dominated 
by a subset of IgM+ B cells. However, towards the end of the 1st cycle, initial class-switching events were observed 
with small but detectable increase in IgG+ and IgA+ cells. During the 2nd cycle, we observed a major expansion of 
IgG+ CD27+ memory B cells, and this subset remained the dominant population of KLH-specific B cells up until 
after the end of the follow-up period of the study.
Figure 1. KLH++ B cells produce antibodies that are specific for KLH. (A) KLH++ and KLH−− CD19+ B cells 
from patient 5 and patient 9 were FACS sorted and differentiated into antibody secreting cells (ASCs). Plates 
were coated with either KLH or with anti-IgG, IgM or IgA, after which differentiated KLH++ and KLH−− B 
cells were added to the wells. Subsequently, ASCs secreting anti-KLH and anti-total IgG- (B), anti-KLH and 
anti-total IgM- (D) and anti-KLH and anti-total IgA-antibodies (E) were detected using ELISPOT. For patient 
9, ASCs were enumerated and compared between specific and unspecific conditions (C, F white bars indicate 
KLH-specific ASCs, black bars total ASCs). The number of sorted and ex vivo differentiated cells is indicated 
below ELISPOT photographs. (B,D,E) For each condition two technical replicates with different numbers of 
input cells (indicated below image) are shown. (F) Quantification of 1 well representative for 2 – 3 technical 
replicates with different number of input cells.
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Discussion
KLH is an immunogenic agent with various clinical applications and in-depth knowledge on the dynamics of 
KLH-induced immune responses could aid the understanding of KLH treatment effects.
In this project, we developed a sensitive assay for the ex vivo detection of KLH-specific B cells on the basis of 
the B cell receptor specificity for its cognate antigen and without requirement for B cell pre-stimulation. Using 
fluorescently labeled KLH, we were able to detect KLH-specific B cells after vaccination of stage III melanoma 
patients with ex vivo KLH-loaded dendritic cells and to phenotype those cells. To verify the specificity and sensi-
tivity, we compared our immunoassay to the current gold standard for the detection of antigen-specific memory 
B cells, i.e. memory B cell ELISPOT. ELISPOT analysis of sorted KLH++ B cells revealed that the great majority of 
KLH-stained cells was indeed secreting KLH-specific antibodies, demonstrating the high specificity of the assay. 
To assess the sensitivity, we analyzed the KLH-specific antibody production of total CD19+ B cells and observed 
similar frequencies for both flow cytometry and ELISPOT, suggesting a comparable sensitivity. It should be noted 
that the frequency of KLH-specific IgG+ B cells as measured by flow cytometry was at the lower end of the fre-
quency range as compared to the numbers found by ELISPOT. A potential explanation is that ELISPOT analysis 
involves an in vitro pre-activation step that might introduce bias. The different B cell subsets may not respond 
to the pre-stimulation conditions in the same manner and thus may not expand at a similar rate as shown, for 
instance, by Scholzen et al. using a similar protocol22. On the other hand, our dual staining approach may lead to 
an under-representation of the actual KLH-specific B cells. Finally, we compared the frequency of KLH-specific 
B cells with serum anti-KLH antibody titers measured by ELISA. We observed a strong, positive correlation 
between anti-KLH IgG antibodies and the overall frequency of KLH-specific CD19+ IgG+ B cells and weak corre-
lation between the frequency of KLH-specific B cells and anti-KLH IgA antibodies or anti-KLH IgM serum titers. 
Overall, these experiments suggest that the detection of KLH-specific B cells using fluorescently-labeled KLH is 
feasible, scalable, and in good agreement with established experimental techniques. The advantage of the here 
described flow cytometric analysis of antigen-specific B cells over ELISPOT analysis is the possibility to combine 
quantification with extensive phenotyping and purification of cell subsets.
In this study, we found KLH-specific B cell frequencies of up to 1.32% of the total CD19+ B cell pool and 
of up to 8.93% in the CD19+ IgG+ B cell pool after 3 cycles of DC vaccination. Even 3 months after the last 
vaccination, KLH-specific B cell frequencies remained as high as 0.1% for CD19+ B cells and 0.85% for IgG+ 
CD19+ B cells (data not shown). To put this in perspective, we compared our results with other published studies 
on flow cytometry-based detection of antigen-specific B cells. In healthy volunteers undergoing Tetanus toxoid 
(TT) booster vaccination, for instance, numbers of TT-specific CD19+ B cells peaked at 0.012%; two orders of 
magnitude lower than the numbers of KLH-specific CD19+ B cells we observed17. Of note, the time points after 
booster vaccination may differ between the cited study and ours as exact details are only given for a subset of 
TT-vaccinated volunteers. Other studies examined naturally induced B cell responses, for instance in allergic 
patients under oral immunotherapy. Here, up to 0.3% peanut allergen Arah1– and Arah2-specific CD19+ B cells 
were detected18. Kerkman et al. observed up to 0.06% of CD19+ B cells being specific for a mimic of citrullinated 
protein antigens20. When examining the IgG-specific B cell response in viremic HIV patients, Kardava et al. 
Figure 2. Frequencies of KLH-specific B cells as determined by flow-cytometric analysis are confirmed by 
ELISPOT analysis. CD19+ B cells from patients 2, 9, 10 and 12 after the 3rd cycle of vaccination were sorted 
and differentiated as described. (A) Anti-KLH IgG and total IgG antibody secreting cells were detected using 
ELISPOT and (B) the relative ASC number of both fractions was determined. (C) From this data the KLH-
specific B cell frequency within the IgG+ subset was determined and compared to the frequency of KLH-specific 
B cells as determined by flow cytometric data at the time of sorting, i.e. before differentiation. Error bars show 
standard deviation of 2–4 replicate differentiation cultures.
www.nature.com/scientificreports/
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Figure 3. KLH-specific B cell frequencies correlate with anti-KLH IgG antibody titers in serum. Serum 
titers of anti-KLH IgG antibodies were determined using ELISA and plotted against the frequency of KLH++ 
cells in the indicated B cell subsets. Linear curves were fitted on the data and key regression values are given in 
each plot.
Figure 4. KLH-specific B cells were induced in all vaccinated melanoma patients. KLH-specific B cells 
were measured before vaccination, after the first cycle and after the third cycle. Days indicate the time to 1st 
vaccination. (A) Dot plots of KLH-specific B cells of one representative melanoma patient. (B) Frequencies of 
the KLH-specific B cells within the indicated B cell subsets for 10 melanoma patients.
www.nature.com/scientificreports/
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discovered up to 0.3% of Tetanus- or influenza-specific CD19+ IgG+ B cells19. In the same study, the authors could 
detect up to 6% of CD19+ IgG+ B cells being specific for the HIV antigen gp140. Our results thus confirm the high 
immunogenicity of KLH but also show that direct comparison of specific B cell numbers are difficult between 
studies due to differences in timing and activation state of the immune system.
The KLH-specific B cell maturation patterns we observed in this study closely follow prototypic primary and 
secondary immune responses against a neo-antigen. The primary response was dominated by KLH++ IgM+ B 
Figure 5. Maturation of KLH-specific B cells during repeated DC vaccination. (A) Proportion of different B 
cell subsets of the total B cells before vaccination (Median values of all patients). (B) Proportion of KLH-specific 
B cell subset after the 1st and 3rd cycle of vaccination. (C) In-depth analysis of the development of different B cell 
subsets within KLH-specific and total B cell population after 1st and 3rd cycle of vaccination (n = 10). Whisker 
plots represent median (line), 25% and 75%ile (box) and the minimum and maximum values (whiskers). For 
gating strategy see Supplementary Figure 2.
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cells, which switched to an IgG-dominated response after secondary and tertiary immunization, aligning closely 
with earlier studies on anti-KLH serum antibody levels23,24. Moreover, early KLH-specific IgG+ B cells were pre-
dominantly CD27−, whereas late KLH-specific IgG+ B cells were CD27+. This is in line with the concept that IgG+ 
CD27− B cells underwent one germinal center reaction and become CD27+ upon subsequent antigen exposure 
and additional germinal center reactions21. We also detected relatively high levels of IgA+ KLH-specific B cells 
in early responses, which were not detected at later time points. Although it remains unclear whether this B cell 
subset contracts after subsequent antigen exposure or whether these cells home to other (mucosal) tissues, the 
observed increase in anti-KLH IgA antibody titers in patients after multiple vaccinations argues for the latter 
option. Our data collectively indicate that the employed DC vaccination is inducing an IgG-dominated humoral 
immune response possibly driven by the induction of Th1 cells typically observed during this treatment25. The 
question remains as to how far the induction of KLH-specific B cells early after vaccination can be predictive for 
the clinical response to dendritic cell-based vaccination. Further research in extended cohorts is necessary to 
investigate this.
Although it is generally assumed that the primary activation signal of B cells is direct contact of the B 
cell receptor with its cognate antigen, it should be noted that the patients in our study were never vaccinated 
directly with the soluble KLH antigen. Instead, patients were injected with autologous ex vivo differentiated 
monocyte-derived dendritic cells. Following differentiation, DCs were incubated with soluble KLH, after which 
cells were washed thoroughly. Although this procedure efficiently removes soluble KLH, we still observe robust 
humoral KLH-responses. The mechanism by which KLH is able to induce a B cell response in these patients needs 
thus further investigation.
In summary, this study shows a novel, fast, and robust method to quantify and phenotype circulating 
KLH-specific B cells. The use of flow cytometry does not only allow more in-depth phenotyping of KLH-specific 
B cells, but also allows isolation, functional analysis, molecular profiling, tracking of clonal evolution and produc-
tion of fully human antibodies. By further standardization, the flow cytometric assay presented here may allow 
for inter-institutional comparisons and immunomonitoring of KLH-specific B cell responses. This will help to 
increase our understanding of the human B cell response to KLH and further facilitate the development of novel 
clinical KLH applications.
Figure 6. Dynamics of the KLH-specific B cell response during the course repeated KLH vaccinations in 
patient 5. (A) The frequency of KLH++ B cells and the serum titer of anti-KLH antibodies at different time 
points during the treatment of patient 5 are shown. (B) The distribution of the KLH++ B cells over the different 
B cell subsets during the course of patient 5′ s treatment is shown.
www.nature.com/scientificreports/
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Methods
Patients. Peripheral blood mononuclear cells (PBMCs) or peripheral blood lymphocytes (PBLs) were col-
lected from stage III melanoma patients at different time points during the course of their disease (n = 10). All 
patients underwent immunotherapy using autologous monocyte-derived matured dendritic cells loaded with 
KLH and tumor antigen in our department as described in the original study and indicated in Supplementary 
Table 126. Patients received DCs in three cycles every 6–9 months, with three fortnightly injections per cycle, 
except for the 1st cycle where four injections were given. Patients were World Health Organization perfor-
mance status 0 or 127. The original study (Clinical trial registration number NCT00243594, registration date: 
21.10.2005) was in accordance with relevant guidelines and regulations and approved by the Medical Research 
Ethics Committee (CMO Regio Arnhem-Nijmegen). Patients signed informed consent.
KLH-labeling. KLH protein (Vacmune, Immucothel) was labeled with either FITC or Readilink 700/713 
using the FITC Antibody Labeling Kit (Pierce, 53027) or the ReadiLink 700/713 Antibody Labeling Kit (BioRad, 
135-1008), respectively, following the manufacturer’s instructions.
B cell staining. Cryopreserved PBMCs and PBLs were thawed and washed 2x in Iscove’s Modified Dulbecco’s 
Medium (IMDM) (Gibco) supplemented with 1% fetal bovine serum (FBS) (Greiner Bio-One) and 25 μ g/mL 
DNAse 1 (Roche). The serum lot was pretested for performance. In case of several time points measured for a 
single patient, all samples were processed in one experiment, with the exception of patient 5. Subsequently, cells 
were washed 2x with PBS and dead cells were identified by staining with Fixable Viability Dye eFluor® 780 (eBi-
oscience, 1:2000 in PBS, 100 μ L) at 4 °C for 30 minutes. Cells were washed once with PBS followed by one wash 
with PBS supplemented with 2% FBS (wash buffer). B cells (5–50 · 106) were stained with 10 μ g/mL FITC- and 
1 μ g/mL ReadiLink 700/713-labeled KLH in 120 μ L wash buffer for 30 minutes on ice. Cells were pulse vortexed 
every 5 minutes during incubation. Subsequently, cells were incubated for 20 minutes in a total volume of 200 μ L 
of fluorescently labeled antibodies in wash buffer. See Supplementary Methods for the labeled monoclonal anti-
bodies used in this study. Cells were washed 1x, resuspended in wash buffer and kept at 4 °C for a maximum of 2 h 
before analysis by flow cytometry.
Flow cytometry and gating strategy. Cells were acquired using a LSRII and – for fluorescence-activated 
cell sorting – a FACSAria (both Becton Dickinson) and analyzed with FlowJo software (Tree Star). Per sample, 
between 867,000 and 16,600,000 events were acquired, yielding 38,720–632,000 viable CD19+ B cells. The lym-
phocyte population was gated followed by exclusion of doublets and dead cells. B cells were defined as CD19+ 
CD3−CD14−CD16−CD56− and KLH-specific B cells identified by dual staining for FITC and ReadiLink 700/713 
(Fig. 1). During the 1st vaccination cycle, the frequencies of KLH-specific B cells were relatively low and calcu-
lations were based on up to 30 KLH-specific B cells. B cell subsets were characterized using a gating strategy 
adapted from Berkowska et al. (Supplementary Figure 2 and Supplementary Methods)21.
B cell expansion and ELISPOT. Sorted B cells were quantified and checked for antibody production using 
ELISPOT. See Supplementary Methods for a detailed description of the B cell expansion protocol and ELISPOT 
procedure.
KLH-specific antibody production. The concentration of KLH-specific antibodies was determined by 
ELISA (www.KLHanalysis.com) in patients’ sera before and at various time points after vaccination. Serum 
samples were obtained at a maximum of + /− 10 days before/after the corresponding PBMC samples. See 
Supplementary Methods for a detailed description of the ELISA procedure.
Data Analysis and Statistics. Analysis and presentation of distributions was performed using PRISM for 
windows version 5.03 (GraphPad) and The R Project for Statistical Computing using the ggplot2 and xlsx pack-
ages28–30. For statistical analysis, Spearman’s Rank-Order correlation analysis was employed.
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